{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:12Z","timestamp":1761101052652},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T00:00:00Z","timestamp":1280793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9635-8","type":"journal-article","created":{"date-parts":[[2010,8,2]],"date-time":"2010-08-02T16:47:24Z","timestamp":1280767644000},"page":"1604-1608","source":"Crossref","is-referenced-by-count":12,"title":["Epstein\u2013Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"George M.","family":"Viola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youli","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelty R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"9635_CR1","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1128\/JCM.43.7.3540-3543.2005","volume":"43","author":"E Peres","year":"2005","unstructured":"Peres E, et al. High fatality rate of epstein-bar virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol. 2005;43:3540\u20133.","journal-title":"J Clin Microbiol"},{"key":"9635_CR2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1083-8791(03)00228-3","volume":"9","author":"RA Nash","year":"2003","unstructured":"Nash RA, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003;9:583\u201391.","journal-title":"Biol Blood Marrow Transplant"},{"key":"9635_CR3","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2006-09-045625","volume":"109","author":"P Scheinberg","year":"2007","unstructured":"Scheinberg P, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109:3219\u201324.","journal-title":"Blood"},{"key":"9635_CR4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2007-09-111534","volume":"111","author":"MJ Wondergem","year":"2008","unstructured":"Wondergem MJ, et al. Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. Blood. 2008;111:1739.","journal-title":"Blood"},{"key":"9635_CR5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2008.394","volume":"43","author":"HC Buyck","year":"2009","unstructured":"Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant. 2009;43:813\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"9635_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.20560","volume":"81","author":"E Calistri","year":"2006","unstructured":"Calistri E, et al. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol. 2006;81:355\u20137.","journal-title":"Am J Hematol"},{"key":"9635_CR7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1701554","volume":"23","author":"TG Gross","year":"1999","unstructured":"Gross TG, et al. B-cell lymphoproliferative disorders following haematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"9635_CR8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3476(97)70173-2","volume":"131","author":"GJ Boyle","year":"1997","unstructured":"Boyle GJ, et al. Post transplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr. 1997;131:309\u201313.","journal-title":"J Pediatr"},{"key":"9635_CR9","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis RE, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208\u201316.","journal-title":"Blood"},{"key":"9635_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.56.082103.104727","volume":"56","author":"S Gottschalk","year":"2005","unstructured":"Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29\u201344.","journal-title":"Annu Rev Med"},{"key":"9635_CR11","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","volume":"21","author":"KS Baker","year":"2003","unstructured":"Baker KS, et al. New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352\u20138.","journal-title":"J Clin Oncol"},{"key":"9635_CR12","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V87.9.3633.bloodjournal8793633","volume":"87","author":"S Bhatia","year":"1996","unstructured":"Bhatia S, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633\u20139.","journal-title":"Blood"},{"key":"9635_CR13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/sj.bmt.1701258","volume":"21","author":"RJ Hauke","year":"1998","unstructured":"Hauke RJ, et al. Epstein-Barr virus associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant. 1998;21:1271\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"9635_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00365540600978906","volume":"39","author":"A Kinch","year":"2007","unstructured":"Kinch A, et al. Post-transplant lymphoproliferative disease and other Epstein-Barr virus disease in allogenic hematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007;39:235\u201344.","journal-title":"Scand J Infect Dis"},{"key":"9635_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bmt.1704089","volume":"32","author":"E Juvonen","year":"2003","unstructured":"Juvonen E, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant. 2003;32:97\u2013102.","journal-title":"Bone Marrow Transplant"},{"key":"9635_CR16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2141.1997.2153034.x","volume":"98","author":"M Briz","year":"1997","unstructured":"Briz M, et al. Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukaemia. Br J Haematol. 1997;98:485\u20137.","journal-title":"Br J Haematol"},{"key":"9635_CR17","doi-asserted-by":"crossref","unstructured":"Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol (electronic version available on April 7, 2010).","DOI":"10.1007\/s00277-010-0944-y"},{"key":"9635_CR18","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V91.10.3654","volume":"91","author":"KG Lucas","year":"1998","unstructured":"Lucas KG, et al. Semiquantitative Epstein\u2013Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654\u201361.","journal-title":"Blood"},{"key":"9635_CR19","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","volume":"103","author":"HJ Wagner","year":"2004","unstructured":"Wagner HJ, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979\u201381.","journal-title":"Blood"},{"key":"9635_CR20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1705289","volume":"37","author":"DM Weinstock","year":"2006","unstructured":"Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539\u201346.","journal-title":"Bone Marrow Transplant"},{"key":"9635_CR21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/j.1600-6143.2005.01002.x","volume":"5","author":"TC Lee","year":"2005","unstructured":"Lee TC, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5:2222\u20138.","journal-title":"Am J Transplant"},{"key":"9635_CR22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","volume":"345","author":"F Suzan","year":"2001","unstructured":"Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder. N Engl J Med. 2001;345:1000.","journal-title":"N Engl J Med"},{"key":"9635_CR23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/522531","volume":"45","author":"SM Aalto","year":"2007","unstructured":"Aalto SM, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogenic stem cell transplant recipients. Clin Infect Dis. 2007;45:1305\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9635-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9635-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T21:54:27Z","timestamp":1591739667000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9635"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9635-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,3]]}}}